Skip to main content
Erschienen in: Pediatric Nephrology 10/2014

01.10.2014 | Original Article

Effect of CYP3A5 genotype, steroids, and azoles on tacrolimus in a pediatric renal transplant population

verfasst von: Shwetal Lalan, Susan Abdel-Rahman, Andrea Gaedigk, J. Steven Leeder, Bradley A. Warady, Hongying Dai, Douglas Blowey

Erschienen in: Pediatric Nephrology | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Numerous studies have described the impact of cytochrome P450 3A5 (CYP3A5) genotype on Tacrolimus (TAC) exposure. The purpose of this study was to conduct a comprehensive analysis of genetic and non-genetic factors affecting the TAC dose–exposure relationship over the first year post pediatric renal transplant.

Methods

Data were collected retrospectively for the first year post-transplant in pediatric renal transplant patients receiving TAC maintenance immunosuppression. The effect of CYP3A5 genotype (CYP3A5*3 and *6 alleles), age, azoles, and corticosteroids on TAC trough concentration normalized for dose (TAC Co/D ng/ml/mg/kg/day) was assessed using a linear mixed model.

Results

Over time, TAC Co/D was lower in recipients with CYP3A5*1/*3 genotype compared to those with CYP3A5*3/*3 genotype (44.5 ± 14.4 vs. 107.6 ± 6.4, p = 0.03), increased in patients >12 years of age compared to < 12 years (93.9 ± 8.7 vs. 53.1 ± 12.9, p = 0.007), and decreased by concomitant corticosteroids (69.5 ± 12.7 vs. 89.9 ± 20.0, p = 0.04). The observed increased TAC Co/D in the presence of azoles (271 ± 41 vs. 111 ± 91, p = 0.016) could be attributed to clotrimazole.

Conclusions

Multiple factors, including CYP3A5 genotype, and age, influence TAC Co/D in pediatric kidney transplant recipients. Clotrimazole administered as troches also contribute to TAC Co/D variability.
Literatur
1.
Zurück zum Zitat Barraclough KA, Staatz CE, Johnson DW, Lee KJ, McWhinney BC, Ungerer JP, Hawley CM, Campbell SB, Leary DR, Isbel NM (2012) Kidney transplant outcomes are related to tacrolimus, mycophenolic acid and prednisolone exposure in the first week. Transpl Int 25(11):1182–93. Barraclough KA, Staatz CE, Johnson DW, Lee KJ, McWhinney BC, Ungerer JP, Hawley CM, Campbell SB, Leary DR, Isbel NM (2012) Kidney transplant outcomes are related to tacrolimus, mycophenolic acid and prednisolone exposure in the first week. Transpl Int 25(11):1182–93.
2.
Zurück zum Zitat Staatz CE, Goodman LK (2010) Tett SE. Effect of CYP3A and ABCB1 single-nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet 49(3):141–75. Staatz CE, Goodman LK (2010) Tett SE. Effect of CYP3A and ABCB1 single-nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet 49(3):141–75.
3.
Zurück zum Zitat Israni AK, Riad SM, Leduc R, Oetting WS, Guan W, Schladt D, Matas AJ, Jacobson PA, DeKAF Genomics Investigators (2013) Tacrolimus trough levels after month 3 as a predictor of acute rejection following kidney transplantation: a lesson learned from DeKAF Genomics. Transpl Int. doi:10.1111/tri.12155 PubMed Israni AK, Riad SM, Leduc R, Oetting WS, Guan W, Schladt D, Matas AJ, Jacobson PA, DeKAF Genomics Investigators (2013) Tacrolimus trough levels after month 3 as a predictor of acute rejection following kidney transplantation: a lesson learned from DeKAF Genomics. Transpl Int. doi:10.​1111/​tri.​12155 PubMed
4.
Zurück zum Zitat Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B (2004) Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4:378PubMedCrossRef Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B (2004) Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4:378PubMedCrossRef
5.
Zurück zum Zitat U.S. Renal Data System, USRDS (2013) Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2013 U.S. Renal Data System, USRDS (2013) Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2013
6.
Zurück zum Zitat Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR (2003) The natural history of chronic allograft nephropathy. N Engl J Med 349(24):2326–33PubMedCrossRef Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR (2003) The natural history of chronic allograft nephropathy. N Engl J Med 349(24):2326–33PubMedCrossRef
7.
Zurück zum Zitat Gijsen VM, Hesselink DA, Croes K, Koren G, de Wildt SN (2013) Prevalence of renal dysfunction in tacrolimus-treated pediatric transplant recipients: a systematic review. Pediatr Transplant 17(3):205–15. PubMedCrossRef Gijsen VM, Hesselink DA, Croes K, Koren G, de Wildt SN (2013) Prevalence of renal dysfunction in tacrolimus-treated pediatric transplant recipients: a systematic review. Pediatr Transplant 17(3):205–15. PubMedCrossRef
8.
Zurück zum Zitat Barbarino JM, Staatz CE, Venkataramanan R, Klein TE, Altman RB (2013) PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet Genomics 23(10):563–85 Barbarino JM, Staatz CE, Venkataramanan R, Klein TE, Altman RB (2013) PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet Genomics 23(10):563–85
9.
Zurück zum Zitat Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P et al (2003) Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 3(4):477–83PubMedCrossRef Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P et al (2003) Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 3(4):477–83PubMedCrossRef
10.
Zurück zum Zitat Gijsen V, Mital S, van Schaik RH, Soldin OP, Soldin SJ, van der Heiden IP, Nulman I, Koren G, de Wildt SN (2011) Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients. J Heart Lung Transplant 30(12):1352–9. PubMedCrossRefPubMedCentral Gijsen V, Mital S, van Schaik RH, Soldin OP, Soldin SJ, van der Heiden IP, Nulman I, Koren G, de Wildt SN (2011) Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients. J Heart Lung Transplant 30(12):1352–9. PubMedCrossRefPubMedCentral
11.
Zurück zum Zitat Zhao W, Elie V, Roussey G, Brochard K, Niaudet P, Leroy V, Loirat C, Cochat P, Cloarec S, André JL, Garaix F, Bensman A, Fakhoury M, Jacqz-Aigrain E (2009) Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther 86(6):609–18. PubMedCrossRef Zhao W, Elie V, Roussey G, Brochard K, Niaudet P, Leroy V, Loirat C, Cochat P, Cloarec S, André JL, Garaix F, Bensman A, Fakhoury M, Jacqz-Aigrain E (2009) Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther 86(6):609–18. PubMedCrossRef
12.
Zurück zum Zitat García-Roca P, Medeiros M, Reyes H, Rodríguez-Espino BA, Alberú J, Ortiz L, Vásquez-Perdomo M et al (2012) CYP3A5 polymorphism in Mexican renal transplant recipients and its association with tacrolimus dosing. Arch Med Res 43(4):283–7. PubMedCrossRef García-Roca P, Medeiros M, Reyes H, Rodríguez-Espino BA, Alberú J, Ortiz L, Vásquez-Perdomo M et al (2012) CYP3A5 polymorphism in Mexican renal transplant recipients and its association with tacrolimus dosing. Arch Med Res 43(4):283–7. PubMedCrossRef
13.
Zurück zum Zitat Ferraris JR, Argibay PF, Costa L, Jimenez G, Coccia PA, Ghezzi LF, Ferraris V, Belloso WH, Redal MA, Larriba JM (2011) Influence of CYP3A5 polymorphism on tacrolimus maintenance doses and serum levels after renal transplantation: age dependency and pharmacological interaction with steroids. Pediatr Transplant 15(5):525–32.PubMedCrossRef Ferraris JR, Argibay PF, Costa L, Jimenez G, Coccia PA, Ghezzi LF, Ferraris V, Belloso WH, Redal MA, Larriba JM (2011) Influence of CYP3A5 polymorphism on tacrolimus maintenance doses and serum levels after renal transplantation: age dependency and pharmacological interaction with steroids. Pediatr Transplant 15(5):525–32.PubMedCrossRef
14.
Zurück zum Zitat de Wildt SN, van Schaik RH, Soldin OP, Soldin SJ, Brojeni PY, van der Heiden IP, Parshuram C, Nulman I, Koren G (2011) The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation. Eur J Clin Pharmacol 67(12):1231–41.PubMedCrossRefPubMedCentral de Wildt SN, van Schaik RH, Soldin OP, Soldin SJ, Brojeni PY, van der Heiden IP, Parshuram C, Nulman I, Koren G (2011) The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation. Eur J Clin Pharmacol 67(12):1231–41.PubMedCrossRefPubMedCentral
15.
Zurück zum Zitat Turolo S, Tirelli AS, Ferraresso M, Ghio L, Belingheri M, Groppali E, Torresani E, Edefonti A (2010) Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. Pharmacol Rep 62(6):1159–69PubMedCrossRef Turolo S, Tirelli AS, Ferraresso M, Ghio L, Belingheri M, Groppali E, Torresani E, Edefonti A (2010) Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. Pharmacol Rep 62(6):1159–69PubMedCrossRef
16.
Zurück zum Zitat Fukudo M, Yano I, Masuda S, Goto M, Uesugi M, Katsura T, Ogura Y, Oike F, Takada Y, Egawa H, Uemoto S, Inui K (2006) Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin Pharmacol Ther 80(4):331–45PubMedCrossRef Fukudo M, Yano I, Masuda S, Goto M, Uesugi M, Katsura T, Ogura Y, Oike F, Takada Y, Egawa H, Uemoto S, Inui K (2006) Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin Pharmacol Ther 80(4):331–45PubMedCrossRef
17.
Zurück zum Zitat Ferraresso M, Tirelli A, Ghio L, Grillo P, Martina V, Torresani E, Edefonti A (2007) Influence of the CYP3A5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients. Pediatr Transplant 11(3):296–300PubMedCrossRef Ferraresso M, Tirelli A, Ghio L, Grillo P, Martina V, Torresani E, Edefonti A (2007) Influence of the CYP3A5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients. Pediatr Transplant 11(3):296–300PubMedCrossRef
18.
Zurück zum Zitat Kausman JY, Patel B, Marks SD (2008) Standard dosing of tacrolimus leads to overexposure in pediatric renal transplantation recipients. Pediatr Transplant 12(3):329–35. Kausman JY, Patel B, Marks SD (2008) Standard dosing of tacrolimus leads to overexposure in pediatric renal transplantation recipients. Pediatr Transplant 12(3):329–35.
19.
Zurück zum Zitat Naesens M, Salvatierra O, Li L, Kambham N, Concepcion W, Sarwal M (2008) Maturation of dose-corrected tacrolimus predose trough levels in pediatric kidney allograft recipients. Transplantation 85(8):1139–45. Naesens M, Salvatierra O, Li L, Kambham N, Concepcion W, Sarwal M (2008) Maturation of dose-corrected tacrolimus predose trough levels in pediatric kidney allograft recipients. Transplantation 85(8):1139–45.
20.
Zurück zum Zitat Jain AB, Fung JJ, Tzakis AG Venkataramanan R, Abu-Elmagd K, Alessiani M, Reyes J, Irish W, Warty V, Mehta S, Todo S, Starzl TE (1991) Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. Transplant Proc 23:2763–6 Jain AB, Fung JJ, Tzakis AG Venkataramanan R, Abu-Elmagd K, Alessiani M, Reyes J, Irish W, Warty V, Mehta S, Todo S, Starzl TE (1991) Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. Transplant Proc 23:2763–6
21.
Zurück zum Zitat Przepiorka D, Blamble D, Hilsenbeck S, Danielson M, Krance R, Chan KW (2000) Tacrolimus clearance is age-dependent within the pediatric population. Bone Marrow Transplant 26:601–5 Przepiorka D, Blamble D, Hilsenbeck S, Danielson M, Krance R, Chan KW (2000) Tacrolimus clearance is age-dependent within the pediatric population. Bone Marrow Transplant 26:601–5
22.
Zurück zum Zitat Guy-Viterbo V, Scohy A, Verbeeck RK, Reding R, Wallemacq P, Musuamba FT (2013) Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation. Eur J Clin Pharmacol 69(8):1533–42.PubMedCrossRef Guy-Viterbo V, Scohy A, Verbeeck RK, Reding R, Wallemacq P, Musuamba FT (2013) Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation. Eur J Clin Pharmacol 69(8):1533–42.PubMedCrossRef
23.
Zurück zum Zitat Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, Choukroun G, Toupance O, Touchard G, Alberti C, Le Pogamp P, Moulin B, Le Meur Y, Hang AE, Subra JF, Beaune P, Legendre C (2010) Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 87(6):721–6. Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, Choukroun G, Toupance O, Touchard G, Alberti C, Le Pogamp P, Moulin B, Le Meur Y, Hang AE, Subra JF, Beaune P, Legendre C (2010) Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 87(6):721–6.
24.
Zurück zum Zitat Pichard L, Fabre I, Daujat M, Domergue J, Joyeux H, Maurel P (1992) Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol 41(6):1047–55PubMed Pichard L, Fabre I, Daujat M, Domergue J, Joyeux H, Maurel P (1992) Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol 41(6):1047–55PubMed
25.
Zurück zum Zitat Kim JS, Aviles DH, Silverstein DM, Leblanc PL, Vehaskari VM (2005) Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant 9(2):162–9 Kim JS, Aviles DH, Silverstein DM, Leblanc PL, Vehaskari VM (2005) Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant 9(2):162–9
26.
Zurück zum Zitat Garg U, Munar A, Frazee CC 3rd (2012) Simultaneous determination of cyclosporine, sirolimus, and tacrolimus in whole blood using liquid chromatography-tandem mass spectrometry. Methods Mol Biol 902:167–73PubMedCrossRef Garg U, Munar A, Frazee CC 3rd (2012) Simultaneous determination of cyclosporine, sirolimus, and tacrolimus in whole blood using liquid chromatography-tandem mass spectrometry. Methods Mol Biol 902:167–73PubMedCrossRef
27.
Zurück zum Zitat Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem YF (2004) Alterations of CYP3A4 and P-glycoprotein activity in vivo with time in renal graft recipients. Kidney Int 66(1):433–40PubMedCrossRef Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem YF (2004) Alterations of CYP3A4 and P-glycoprotein activity in vivo with time in renal graft recipients. Kidney Int 66(1):433–40PubMedCrossRef
28.
Zurück zum Zitat Lamba JK, Lin YS, Schuetz EG, Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54(10):1271–94PubMedCrossRef Lamba JK, Lin YS, Schuetz EG, Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54(10):1271–94PubMedCrossRef
29.
Zurück zum Zitat Dai Y, Hebert MF, Isoherranen N, Davis CL, MArch C, Shen DD, Thummel KE (2006) Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 34:836–47PubMedCrossRef Dai Y, Hebert MF, Isoherranen N, Davis CL, MArch C, Shen DD, Thummel KE (2006) Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 34:836–47PubMedCrossRef
30.
Zurück zum Zitat Werk AN, Lefeldt S, Bruckmuller, Hemmrich-Stanisak G, Franke A, Roos M, Küchle C, Steubl D, Schaderer C, Bräsen JH, Heemann U, Cascorbi I, Renders L (2013) Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patients with severely diminished tacrolimus clearance. Clin Pharmacol Ther. doi:10.1038/clpt.2013.210 PubMed Werk AN, Lefeldt S, Bruckmuller, Hemmrich-Stanisak G, Franke A, Roos M, Küchle C, Steubl D, Schaderer C, Bräsen JH, Heemann U, Cascorbi I, Renders L (2013) Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patients with severely diminished tacrolimus clearance. Clin Pharmacol Ther. doi:10.​1038/​clpt.​2013.​210 PubMed
31.
Zurück zum Zitat Elens L, Capron A, van Schaik RH, De Meyer M, De Pauw L, Eddour DC, Latinne D, Wallemacq P, Mourad M, Haufroid V (2013) Impact of CYP3A4*22 Allele on Tacrolimus Pharmacokinetics in Early Period after Renal Transplantation: Toward Updated Genotype-Based Dosage Guidelines. Ther Drug Monit 35(5):608–16.PubMed Elens L, Capron A, van Schaik RH, De Meyer M, De Pauw L, Eddour DC, Latinne D, Wallemacq P, Mourad M, Haufroid V (2013) Impact of CYP3A4*22 Allele on Tacrolimus Pharmacokinetics in Early Period after Renal Transplantation: Toward Updated Genotype-Based Dosage Guidelines. Ther Drug Monit 35(5):608–16.PubMed
32.
Zurück zum Zitat Kuypers DR, de Jonge H, Naesens M, Vanrenterghem Y (2008) Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenet Genomics 18(10):861–8.PubMedCrossRef Kuypers DR, de Jonge H, Naesens M, Vanrenterghem Y (2008) Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenet Genomics 18(10):861–8.PubMedCrossRef
33.
Zurück zum Zitat Vasquez E, Pollak R, Benedetti E (2001) Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients. Clin Transplant 15(2):95–9PubMedCrossRef Vasquez E, Pollak R, Benedetti E (2001) Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients. Clin Transplant 15(2):95–9PubMedCrossRef
34.
Zurück zum Zitat Gibbs MA, Kunze KL, Howald WN, Thummel KE (1999) Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole. Drug Metab Dispos 27(5):596–9PubMed Gibbs MA, Kunze KL, Howald WN, Thummel KE (1999) Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole. Drug Metab Dispos 27(5):596–9PubMed
35.
Zurück zum Zitat Gubbins PO, Heldenbrand S (2010) Clinically relevant drug interactions of current antifungal agents. Mycoses 53(2):95–113PubMedCrossRef Gubbins PO, Heldenbrand S (2010) Clinically relevant drug interactions of current antifungal agents. Mycoses 53(2):95–113PubMedCrossRef
36.
Zurück zum Zitat Zheng S, Tasnif Y, Hebert MF, Davis CL, Shitara Y, Calamia JC, Lin YS, Shen DD, Thummel KE (2012) Measurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition. Clin Pharmacol Ther 92:737–45PubMedCrossRefPubMedCentral Zheng S, Tasnif Y, Hebert MF, Davis CL, Shitara Y, Calamia JC, Lin YS, Shen DD, Thummel KE (2012) Measurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition. Clin Pharmacol Ther 92:737–45PubMedCrossRefPubMedCentral
Metadaten
Titel
Effect of CYP3A5 genotype, steroids, and azoles on tacrolimus in a pediatric renal transplant population
verfasst von
Shwetal Lalan
Susan Abdel-Rahman
Andrea Gaedigk
J. Steven Leeder
Bradley A. Warady
Hongying Dai
Douglas Blowey
Publikationsdatum
01.10.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Nephrology / Ausgabe 10/2014
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-014-2827-2

Weitere Artikel der Ausgabe 10/2014

Pediatric Nephrology 10/2014 Zur Ausgabe

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.